Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 18/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.75 |
| ▸ | RECQL | P46063 | 2/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.75 |
| ▸ | GLA | P06280 | 2/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 1/20 | 0.74 |
| ▸ | RAB9A | P51151 | 1/20 | 0.74 |
| ▸ | BLM | P54132 | 1/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | CASP1 | P29466 | 1/20 | 0.72 |
| ▸ | CASP7 | P55210 | 1/20 | 0.72 |
| ▸ | HBB | P68871 | 1/20 | 0.72 |
| ▸ | TP53 | P04637 | 1/20 | 0.72 |
| ▸ | HPGD | P15428 | 1/20 | 0.72 |
| ▸ | STAT6 | P42226 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27420812 | 1.00 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL27603460 | 0.92 | TOP1 (0.85) | TOP1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6599316 | 0.92 | TOP1 (0.85) | TOP1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL1007033 | 0.90 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL27650420 | 0.90 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL27451416 | 0.89 | TOP1 (0.79) | TOP1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL29056165 | 0.88 | TOP1 (0.82) | TOP1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL27170416 | 0.88 | TOP1 (0.81) | TOP1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL18251452 | 0.87 | TOP1 (0.80) | TOP1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL16214743 | 0.87 | TOP1 (0.80) | TOP1MEN1KMT2ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007095389-A2 | TREATMENT OF HYPERPROLIFERATIVE DISEASES WITH CAMPTOTHECINE N-OXIDE AND ANALOGS | NOVACEA, INC. (US) | 2007-08-23 | — | — | WO | claimed |
| EP-2042194-A2 | Treatment of refractory human tumors with epidermal growth factor receptor antagonists | IMCLONE SYSTEMS, INC. (US) | 2009-04-01 | — | — | EP | disclosed |
| WO-2007095389-A2 | TREATMENT OF HYPERPROLIFERATIVE DISEASES WITH CAMPTOTHECINE N-OXIDE AND ANALOGS | NOVACEA, INC. (US) | 2007-08-23 | — | — | WO | disclosed |
| US-20050112120-A1 | Treatment of refractory human tumors with epidermal growth factor receptor antagonists | IMCLONE LLC | 2005-05-26 | — | — | US | disclosed |
| EP-1218032-A4 | TREATMENT OF REFRACTORY HUMAN TUMORS WITH EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONISTS | IMCLONE SYSTEMS INC (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20030202973-A1 | Treatment of refractory human tumors with epidermal growth factor receptor and HER1 mitogenic ligand (EGFRML) antagonists | DR. GEORGE PIECZENIK (US) | 2003-10-30 | — | — | US | disclosed |
| US-20030157104-A1 | Treatment of refractory human tumors with epidermal growth factor receptor antagonists | WAKSAL HARLAN W (US) | 2003-08-21 | — | — | US | disclosed |
| EP-0831825-B1 | PHARMACEUTICAL FORMULATIONS OF HIGHLY LIPOPHILIC CAMPTOTHECIN DERIVATIVES | BIONUMERIK PHARMACEUTICALS INC (US) | 2003-04-23 | — | — | EP | disclosed |
| EP-1218032-A1 | TREATMENT OF REFRACTORY HUMAN TUMORS WITH EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONISTS | IMCLONE SYSTEMS, INC. (US) | 2002-07-03 | — | — | EP | disclosed |
| US-20020012663-A1 | Treatment of refractory human tumors with epidermal growth factor receptor antagonists | WAKSAL HARLAN W (US) | 2002-01-31 | — | — | US | disclosed |
| WO-2000069459-A1 | TREATMENT OF REFRACTORY HUMAN TUMORS WITH EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONISTS | IMCLONE SYSTEMS INCORPORATED (US) | 2000-11-23 | — | — | WO | disclosed |
| US-5958937-A | SOLUTION OF LIPOPHILIC, POORLY WATER SOLUBLE A-RING SUBSTITUTED CAMPTOTHECIN DERIVATIVES DISSOLVED OR SUSPENDED IN N-METHYL-2-PYRROLIDINONE; USE AS PHARMACEUTICAL FOR TREATING CANCER IN HUMANS | BIONUMERIK PHARMACEUTICALS, INC. | 1999-09-28 | — | — | US | disclosed |
| US-5955467-A | INJECTABLE STERILE SOLUTIONS, ANTITUMOR COMPOSITIONS, SOLUTIONS AND SUSPENSIONS COMPRISING N-METHYL-2-PYRROLIDINONE AND A HIGHLY LIPOPHILIC CAMPTOTHECIN DERIVATIVE USED TO TREAT HUMAN CANCERS | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1999-09-21 | — | — | US | disclosed |
| US-5900419-A | SOLUTION OR SUSPENSION OF CAMPTOTHECIN DERIVATIVE IN N-METHYL-2-PYRROLIDONE, PHARMACEUTICALLY ACCEPTABLE ACID, POLYETHYLENE GLYCOL, LOWER ALCOHOL OR BENZYL ALCOHOL | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1999-05-04 | — | — | US | disclosed |
| US-5880133-A | MIXTURE CONTAINING N-METHYLPYRROLIDONE AND AN ACID EXCIPIENT | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1999-03-09 | — | — | US | disclosed |
| US-5859023-A | Formulations and compositions of poorly water soluble camptothecin derivatives | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1999-01-12 | — | — | US | disclosed |
| US-5859022-A | SUSPENSIONS IN N-METHYL-2-PYRROLIDINONE; FOR ADMINISTRATION TO A PATIENT WITH CANCER | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1999-01-12 | — | — | US | disclosed |
| EP-0831825-A1 | PHARMACEUTICAL FORMULATIONS OF HIGHLY LIPOPHILIC CAMPTOTHECIN DERIVATIVES | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| US-5726181-A | Formulations and compositions of poorly water soluble camptothecin derivatives | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1998-03-10 | — | — | US | disclosed |
| WO-1996039143-A1 | PHARMACEUTICAL FORMULATIONS OF HIGHLY LIPOPHILIC CAMPTOTHECIN DERIVATIVES | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1996-12-12 | — | — | WO | disclosed |